Early Renal Replacement Therapy in COVID 19 Patients With AKI Does it Improve the Outcome?

Early Renal Replacement Therapy in COVID 19 Patients With AKI Improves the Prognosis of the Disease

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05274685

Enrollment

100

Registered

2022-03-10

Start date

2021-06-01

Completion date

2022-01-01

Last updated

2022-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multi Organ Failure

Brief summary

patients will be divided into two equal groups, each group including 50 adult patients with a confirmed diagnosis of covid, patients with acute kidney injury, the first group will be treated with early hemodialysis, second group will be conservative until there is an urgent need for dialysis

Interventions

PROCEDUREhaemodialysis

continuous venovenous hemodiafiltration (CVVHDF) at a prescribed dose of 30-35 mL/kg/h of effluent and with regional citrate anticoagulation

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* adult patients (≥18 years old) with confirmed severe acute respiratory syndrome coronavirus 2 infections admitted to the ICU.

Exclusion criteria

* •Malignancy. * Immuno-deficiency diseases. * Chronic diabetic, cardiac and hypertensive patients * autoimmune diseases.

Design outcomes

Primary

Measure	Time frame	Description
reduction of Sequential Organ Failure Assessment Score	2 weeks	prevention of multi-organ failure associated with covid including respiratorym circulatory, liver and renal failure

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026